CRISPR Therapeutics AG

CRSP

Company Profile

  • Business description

    Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

  • Contact

    Baarerstrasse 14
    ZugCH-6300
    CHE

    T: +41 415613277

    E: [email protected]

    https://www.crisprtx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    407

CRISPR Therapeutics AG News & Analysis

stocks

11 stocks to examine through a sustainability lens

Investors can use ESG information in many useful ways.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,377.4060.700.73%
CAC 407,274.4819.89-0.27%
DAX 4019,884.7585.11-0.43%
Dow JONES (US)42,840.26498.021.18%
FTSE 1008,084.6120.71-0.26%
HKSE19,720.7031.81-0.16%
NASDAQ19,572.60199.831.03%
Nikkei 22539,040.72338.820.88%
NZX 50 Index12,927.4223.310.18%
S&P 5005,930.8563.771.09%
S&P/ASX 2008,126.8059.800.74%
SSE Composite Index3,368.071.96-0.06%

Market Movers